poisar

Stocks · News reference

Nkarta Announces Three NKX019 Presentations At ACR Convergence 2026 On November 6-11, Including Two Oral Presentations On Ntrust Phase 1/2 Safety And Idiopathic Inflammatory Myopathy Activity

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NKTX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

    Nkarta, Inc. announced selection for three scientific presentations at ACR Convergence 2026 in November, including two oral presentations on NKX019's safety profile and clinical activity in idiopathic inflammatory myopathy, and one poster presentation on systemic sclerosis. The company is advancing NKX019, an allogeneic CAR-NK cell therapy targeting CD19 in B-cell-mediated autoimmune diseases, with enrollment ongoing in the Ntrust Phase 1/2 clinical trials across multiple indications.

    NKTX